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Summary
Introduction. — Coronary revascularization surgery is a palliative treatment modality which
should not preclude efforts to treat atherosclerosis. 
Aim. — To assess ongoing cardiovascular risk factors after coronary artery bypass surgery and
develop a strategy to attenuate such factors.
Methods. — 108 patients requiring a coronary artery bypass were included: 2 died soon after
surgery and 6 were excluded for personal reasons. 100 patients were re-admitted into hospital
7 months after surgery for risk factor assessment. Eight months later, they were re-contacted
by telephone (systematic follow-up) for a re-assessment. 
Results. — The population consisted of 77 men with an average age of 64±11 years. Prior to the
operation, the known risk factors were: smoking 34%; HBP 61%; cholesterol 47%; diabetes 30%;
obesity 25%. 
During their hospital stay six months after the procedure: 91% of the patients had at least one
lipid metabolism abnormality. New-onset diabetes was diagnosed in 5%. Blood pressure was
uncontrolled in 18% and 10% were still smoking. Patients tended to be putting on weight and
55% engaged in little or no physical activity. 
Systematic follow-up: lipid metabolism had normalized in 70% of the patients. Blood glucose
levels were significantly lower. Blood pressure was uncontrolled in 9% and 4% were still smoking.
Their weight had stabilized and 65% were engaging in moderate-to-strenuous physical activity. 
Conclusion. — Inadequate attention is paid to risk factors after coronary artery bypass surgery.
A short hospital stay including a cardiovascular evaluation and education about risk factors has
a positive impact on the management of atherosclerosis in the medium term.
© 2008 Published by Elsevier Masson SAS.
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Résumé
Introduction. — La revascularisation coronarienne chirurgicale reste un traitement palliatif qui
ne doit pas occulter les objectifs de traitement de la maladie athéroscléreuse. 
But. — Évaluer le devenir des facteurs de risque cardiovasculaire après pontages coronariens et
optimiser une stratégie de réduction de ces facteurs.
Méthode. — Cent huit patients nécessitant des pontages coronariens ont été inclus. Deux sont
décédés précocement après chirurgie, 6 sont exclus pour raisons personnelles, 100 patients ont
été hospitalisés 7 mois après pontages pour évaluation des facteurs de risque. Ils sont contactés
par téléphone (suivi systématique) 8 mois plus tard pour une nouvelle évaluation. 
Résultats. — La population était constituée de 77 hommes dont l’âge moyen était de 64 ± 11 ans.
Les facteurs de risque préopératoire connus étaient : tabac 34 %, HTA 61 %, cholestérol 47 %,
diabète 30 %, obésité 25 %. 
Lors de leur hospitalisation à 6 mois de l’intervention, 91 % des patients présentaient au moins
une anomalie du métabolisme lipidique. Chez 5 % des patients, un diabète était découvert ;
18 % présentaient une tension artérielle non contrôlée et 10 % fumaient encore activement. Les
patients prenaient du poids et leur activité physique était nulle ou faible dans 55 % des cas. 
Lors de leur suivi systématique, le métabolisme lipidique était normalisé chez 70 % des patients.
La glycémie était significativement plus basse. Neuf pour cent des patients présentaient une
tension artérielle non contrôlée et 4 % fumaient encore activement. Le poids était stabilisé et
65 % avaient une activité physique modérée ou importante. 
Conclusion. — Les facteurs de risque ne sont pas suffisamment pris en charge précocement
après des pontages coronariens. Une courte hospitalisation pour une évaluation cardiovasculaire
et une optimisation de ces facteurs de risque, associée à une éducation des patients, est
bénéfique à moyen terme dans la prise en charge de la maladie athéroscléreuse.
© 2008 Published by Elsevier Masson SAS.
Introduction
The incidences of both ischemic cardiomyopathy and ische-
mic heart failure are on the rise in Western countries [1, 2].
Despite new medical treatment modalities and the develop-
ment of percutaneous revascularization techniques, bypass
surgery remains the reference treatment for coronary heart
disease involving the three arteries [3]. However, this is still
a palliative procedure with as yet unresolved problems. Des-
pite the development of “all-arterial” revascularization
techniques, many situations call for venous grafts which tend
to deteriorate over time leading to the recrudescence of
ischemia [4, 5]. Better understanding of the vascular physio-
logy of venous grafts has helped to improve long-term outco-
mes in myocardial revascularization but this does not make
the global management of cardiovascular risk factors any less
important, one of the goals being to prevent graft deteriora-
tion and exacerbation of the coronary heart disease. It is
well established that global cardiovascular risk factor control
reduces morbidity and mortality [6-8]. Less importance
seems to be attached to such control with patients who have
already undergone surgical myocardial revascularization [6,
7, 9]. Effort needs to be dedicated to reach secondary pre-
vention targets in order to reduce mortality and morbidity
[10]. At our institution, we have instigated an optimal perso-
nalized care program for secondary atherosclerosis preven-
tion. In the work described here, an early evaluation of car-
diovascular risk was programmed after a simple surgical
myocardial revascularization procedure. We established a
new, relatively aggressive strategy for controlling risk factors
involving a short stay in hospital aimed at correcting our
patients’ lack of awareness of the problems, optimizing drug
regimens, and preventing drift in the management of cardio-
vascular risk factors.
Patients and methods
Study design
In this prospective, single-center study, the inclusion criteria
were based on the indication for myocardial revasculariza-
tion by coronary artery bypass surgery, according to ESC and
AHA criteria [3]. All the patients were from the same cardio-
logy department. After the surgical team had reviewed the
patient’s records, the operation was electively scheduled.
For this study, cardiovascular risk factors were exhaustively
reviewed prior to the operation. The patient was revasculari-
zed and after the operation, was transferred to a re-education
unit for a three-week stay. Six months after the procedure,
all patients were re-admitted into the hospital for a review
of their cardiovascular risk factors; at this time, a secondary
prevention program was instigated. Finally, about six months
after this hospital stay, all the patients were telephoned to
gather further information.
Myocardial revascularization surgery
All patients were operated upon by the same surgical team
using exactly the same technique. Myocardial revasculariza-
tion was achieved with extracorporeal circulation at mode-
rate hypothermia (33°C). Cardioplegia was induced using
Breitschneider’s crystalline solution. All patients were imme-
diately transferred to intensive care for postoperative sur-
veillance and were kept in hospital for an average of 8-10
days before discharge to the re-education unit.
Re-admission after six months
Six months after the myocardial revascularization opera-
tion, all patients were hospitalized for three days for an
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exhaustive review of their risk factors and instigation of
the secondary prevention program. Left ventricular ejec-
tion fraction was estimated by both ultrasonography and
isotopic ventriculography. Residual myocardial ischemia
was systematically investigated by MIBI myocardial scinti-
graphy. Every patient’s tobacco consumption, eating
habits and physical activity were evaluated, and body
mass indices were calculated. Blood pressure was monitored
for one hour with the patient lying down; the mean of five
measurements was calculated. Fasting blood was drawn to
measure total, LDL and HDL cholesterol, triglycerides, glu-
cose, glycosylated hemoglobin and fibrinogen. A dietitian
dispensed advice about healthy eating habits, the target
being to cut down fat consumption to less than 30% of
total energy intake with saturated fatty acid intake below
10%. Eating cereals, fiber and fruit was recommended. All
active smokers were given special counseling and nurses
and heart specialists from the department provided them
with information about the associated risk factors. Various
types of information about cardiovascular disease and the
benefit of controlling risk factors were covered. Discharge
treatment regimens were adjusted on the basis of risk fac-
tors and the patients’ cardiac status, in line with ESC and
AHA guidelines [3].
Measurement of the atheroma burden
Carotid atheroma
All patients were given cervical ultrasound examinations by
the same technician before and after the operation. Nar-
rowing was expressed as a percentage of reduction in dia-
meter according to NASCET criteria. The values retained in
this work were stenosis of over 20%.
Arteriopathy in the lower limbs
Systolic Pressure Index measurements were all made with
the patient having been resting in the supine position for at
least five minutes. Posterior and pedal doppler signals were
recorded using a continuous Crayon probe at 8 MHz: hume-
ral pressure was then measured and the SPI calculated (the
ratio between the highest humeral pressure and the highest
ankle pressure).
Systematic monitoring
All patients were re-contacted about six months after this
re-admission into hospital. Information was gathered on all
cardiovascular events as well as on changes in lifestyle and
treatment. Quality of life was also evaluated (SF 36). If a
cardiovascular event had occurred, all the relevant infor-
mation and hospital records were inventoried. 
Statistical analysis
The Protocol was approved by the University Hospital Cen-
ter’s Methodology Group. All the data were analyzed using
descriptive and analytical statistics. Differences in the dis-
tribution of categorical variables were tested using the Chi2
test and those in continuous variables using the paired “t”
test. These analyses were run on Statview 5.0.1 software.
The significance threshold was p<0.05.
Results
Characteristics of the population
A total of 108 successive patients requiring a coronary artery
bypass were included. Two patients died following the pro-
cedure, and six who did not wish to participate in the follow-
up phase were excluded. One hundred patients were there-
fore admitted 207±29 days after their surgery (the Hospitali-
zation Group). They were subsequently re-contacted by tele-
phone 260±15 days later for re-evaluation (Systematic
Follow-up Group). The patients’ characteristics, including
the severity of their condition before the operation and
details of the surgery are given in table 1 and figure 1.
Evaluation of risk factors at 6 months: 
re-admission
Habits
At the time of re-admission, 55% of the patients were
engaging in little or no physical activity. Patients with a
high pre-operative body mass index had continued put-
ting on weight, and 10% of patients were still smoking
(table 2).
Blood pressure
Mean systolic blood pressure was 123.9 mm Hg, and mean
diastolic pressure was 67.8 mm Hg. At the time of admission,
18% of patients had a systolic pressure of over 140 mm Hg
(table 3). Left ventricular hypertrophy was observed in 7% of
patients according to electrical measurements, and in 25%
according to ultrasound.
Laboratory tests
Total, LDL and HDL cholesterol as well as triglyceride levels
are shown in table 3. It is worth noting that LDL cholesterol
was abnormal in nearly 70% of the patients, that HDL was
Table 1 Intervals between surgery, re-admission and
systematic follow-up. Patients’ characteristics, disease
severity, number of bypasses and percentage of venous
grafts.
Interval between surgery 
and re-admission (days)
207.1±29.7
Interval between re-admission 
and systematic follow-up (days)
260±15.4
Interval between surgery and systematic 
follow-up (days)
494±36
Number of patients 100
Mean age (years) 64±11
Females (%) 23
Severity (Euroscore) 5.6±2.5
Mean number of bypasses 2.6±0.6
Venous grafts (%) 60
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abnormal in one patient in two, and that 23% had abnormal
triglycerides; in all, 91% of the re-admitted patients pre-
sented at least one lipid metabolism abnormality six
months after the myocardial revascularization procedure.
Details on glucose metabolism are shown in table 3: new-
onset diabetes was observed in 5% of patients although
mean blood glucose and glycosylated hemoglobin levels
were within the normal range. 
Left ventricular function and residual ischemia
The mean preoperative isotopic ejection fraction was
58.36% ± 16.1% with 11% of patients having an EF of below
40%, and 12% one of between 40 and 50%. The mean posto-
perative EF was not significantly higher but it had signifi-
cantly risen in those with severely impaired function prior
to the operation (i.e. an EF of under 40%, p < 0.05). After
revascularization, 30% of patients were still ischemic: the
various territories involved are shown in figure 2 C.
Peripheral atheromatous burden
With respect to endarteritis obliterans in the lower limbs, 27%
of patients presented an SPI of under 0.9, some with symp-
toms and others without (figure 2 B). Carotid stenosis of over
70% was detected in 10% of patients; such severe narrowing
had not been observed prior to the procedure (figure 2 A).
Treatment
Cardiovascular treatment modalities are shown in figure 3.
72% of patients were taking at least one anti-ischemic drug.
Most of the other 28% were untreated for reasons of intole-
rance. 93% of patients were on at least one anti-platelet or
Figure 1. Mapping of coronary artery bypasses.
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Table 2 Physical activity, body mass index and smoking before and after surgery. NS = not
significant. For physical activity, the p value compares re-admission and systematic follow-
up. For smoking, the p value compares before the operation and re-admission. 
Before the operation Re-admission Systematic follow-up p
Physical activity
Little or none (%) 45 55 35 0.05
Moderate (%) 43 35 52 0.05
Strenuous (%) 12 10 13 NS
Body mass index
Mean (IU) 27.39±3.6 27.9±4.7 27.9±4.1
<25 30 27 26
25-30 45 42 41
>30 25 31 33
Smoking
Never smoked (%) 29 29 29
Former smoker (%) 37 61 67 0.05
Still smoking (%) 34 10 4 NS
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anticoagulant drug, and only 80% were on a statin. In the
20% who were not taking any drug, the main reasons were
adverse muscle or liver reactions. 20% of these patients
were on a weak statin. Only 60% of the patients were taking
a combination of an anti-ischemic drug, an anti-platelet
drug and a statin.
Evaluation of risk factors in the follow-up
Habits
All the patients had stepped up their level of physical acti-
vity with only 35% still engaging in little or no physical acti-
Table 3 Risk factors (laboratory test results and blood pressure parameters) after surgery and at systematic follow-up.
the p value compares re-admission and systematic follow-up.
Before the operation
(n=100)
Re-admission
(n=100)
Systematic follow-up
(n = 100)
p
Total cholesterol (mmol/L) 5.01±1.01 4.98±1.12 4.75±1.1 <0.0001
LDL C (mmol/L) 3.09±1 3.02±1 2.84±0.9 <0.0001
% of patients with LDL >2.58 mmol/L 70 68 55
HDL C (mmol/L) 1.35±0.3 1.34±0.3 1.36±0.3 NS
% of patients with HDL <1.29 mmol/L 50 51 52
Triglycerides (mmol/L) 1.58±0.9 1.51±1.1 1.4±0.9 <0.05
% of patients with TG >1.69 mmol/L 24 23 20 <0.05
Systolic blood pressure (mm Hg) 128.9±14.2 123.9±16.9 131.8±14 <0.01
Diastolic blood pressure (mm Hg) 69.78±8.8 67.8±10.9 77±10 <0.01
% of patients with SBP ≥140 mm Hg 20 18 9 <0.01
Blood glucose (mmol/L) 6.6±4.4 6.4±4.4 5.8±1.6 <0.01
HBA1C (%) 6.8±1.7 6.6±1.4 6.2±1 <0.05
% of diabetic patients 30 35 35
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Figure 2. (A) Evaluation of carotid stenosis. (B) Evaluation of systolic pressure index (SPI). (C) Evaluation of the percentage of ischemic
patients (scintigraphy). (D) NI = not ischemic, I = ischemic, Ant = anterior, Lat = lateral, Inf = inferior, Peri = perilesional.
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vity. Body mass index had stabilized although there had
been a statistically insignificant rise among the obese
patients. Many patients had also given up smoking with only
4% remaining active smokers (table 2).
Blood pressure
The pat ients’  mean systol ic  blood pressure was
131.8±14 mm Hg and their diastolic blood pressure was
77 mm Hg±10 mm Hg, with only 9% having a systolic reading
of over 140 mm Hg.
Laboratory tests
Lipid metabolism had normalized in 70% of patients with
significant drops in LDL cholesterol and triglyceride levels
(table 3). Both blood glucose and glycosylated hemoglobin
had dropped significantly. No new cases of diabe      tes
were observed.
Treatment
Few of the treatment regimens had been changed; the anti-
ischemic regimen had been changed in only two patients
(by switching from a beta-blocker to a calcium channel
inhibitor for reasons of impaired erectile function). 94% of
patients were on a combination of an anti-ischemic drug,
an anti-platelet drug and a statin. 
Cardiac events
Angina had recurred in 5 patients with percutaneous revascu-
larization required in two of them: in both of these procedu-
res, revascularization was carried out in a coronary territory
which had not been bypassed. Two patients had heart failure
with ischemic cardiomyopathy, even though their grafts were
still working satisfactorily. Finally, peripheral arterial revas-
cularization had been practiced in 6 patients suffering from
endarteritis obliterans in the lower limbs (and in whom the
decision to schedule the vascular procedure had been consi-
dered at the time of the coronary surgery) (table 4).
Quality of life
The quality of life evaluation was based on SF 36 [11]. All
the patients filled out the questionnaire and the results
were compared to an age-matched group who had not had
coronary artery bypass surgery. Overall, the patients had
felt well since their surgery with a total SF 36 score of 70%;
results for physical and mental health were comparable.
However, 65% of the patients were still experiencing dyses-
thesia or even pain around the sternotomy. Moreover, they
reported some degree of emotional fragility with 20% repor-
ting frankly reduced life force (figure 4).
Discussion
Myocardial revascularization by coronary artery bypass sur-
gery remains the reference treatment in patients with mul-
tiple arterial involvement. The aim of this procedure is to
improve patients’ quality of life by attenuating the symp-
toms, to decrease coronary mortality, and to arrest the
progression of heart failure resulting from ischemia [3].
Figure 3. Six-month evaluation of the treatment regimen of
patients who have undergone bypass surgery.
BB = beta blocker, IEC = angiotensin converting enzyme inhibitor,
Ica = calcium channel blocker, TNT = nitrate derivatives,
AAP = anti-platelet drug, PLX = Plavix®, AVK = anti vitamin K.
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Table 4 Cardiac events occurring in the systematic fol-
low-up period following surgery.
Cardiovascular events
N = 100 Angina Angina + 
angioplasty
Heart 
failure
Peripheral 
arterial revascu-
larization
Patients (%) 3 2 2 6
Figure 4. Quality of life SF 36. 
A: Specific evaluation. B: Global evaluation. 
Lines represent scores for an age-matched subjects who have not
undergone coronary artery bypass surgery.
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Surgical treatment necessitates the use of arterial and/or
venous grafts. Venous grafts may deteriorate over time,
notably as a result of atherosclerotic involvement of the
graft itself [12]. In these conditions, optimum management
of risk factors can only be of benefit vis-à-vis both the ori-
ginal coronary network as well as the graft elements. We
sought to evaluate the risk of patients after surgery and
optimize risk factor control in order to preclude further
damage to the original coronary network and prevent graft
deterioration. This strategy necessitates a three-day hospi-
tal stay with the instigation of systematic follow-up to
ensure holistic care. A special facility for the investigation,
prevention and treatment of atherosclerosis was therefore
set up at our hospital (Centre d’Exploration, de Prévention
et de Traitement de Atherosclerose - CEPTA). This type of
structure constitutes a precious aid for both “medical” and
“surgical” patients. The follow-up program is run by heart
specialists, specialized nurses and psychologists. This mul-
tidisciplinary approach focuses on personalizing atheroscle-
rotic disease and explaining to each patient why managing
risk factors and complying with the prescribed treatment
regimen is essential. We have observed that, despite opti-
mal discharge prescription given on discharge, following
coronary artery bypass surgery, treatments were often
substantially changed during cardiovascular re-education.
The reasons for this are many and various, often related to
the progressively increasing independence of patients (des-
pite all the information dispensed during the re-education
period). It is very likely that imperfect compliance was
associated with the fact that patients had been provided
with inadequate information or failed to fully understand
what they had been told. After six months, 40% were no
longer taking a full regimen during their hospital stay at the
CEPTA as recommended for patients with coronary heart
disease. About 20-25% of patients had not consulted their
cardiologist since the operation because they had “benefi-
ted” from myocardial revascularization surgery. Our delayed
strategy makes it possible to re-educate the patients about
the chronic nature of atherosclerotic disease, emphasizing
the risk they run of cardiovascular complications despite
the surgery. We observed that, six months after surgery,
the patients were at high cardiovascular risk and attached
little importance to stepping up their level of physical acti-
vity or giving up smoking. The short hospital stay showed
them the expected benefits of simple dietary and lifestyle
measures [13]. Systematic, personalized re-evaluation of
the drug regimen resulted in adequate treatment for coro-
nary heart disease in over 90% of cases and the process hel-
ped foster personalized therapeutic targets. This gave
concrete results in terms of the normalization of lipid meta-
bolism, blood pressure balance and control of blood glucose
levels—all important parameters when it comes to control-
ling risk factors [8, 14-18]. Such holistic care engages
patients’ responsibilities and helps them understand that
the procedure is a palliative measure, thereby “reintegra-
ting” them into the cardiological world and promoting com-
pliance. It also helps identify the highest-risk patients and
points to when monitoring and medical treatment should be
stepped up [8]. This approach therefore helps reduce car-
diovascular risk with about 90% of patients being “respon-
ders” to the strategy. Non-responders should be monitored
more assiduously and more regularly with a view to redu-
cing their risk. The strategy should help us adjust the speci-
fic treatment modalities of a patient who has undergone
myocardial revascularization by coronary artery bypass sur-
gery. A venous graft was installed in 60% of our patients.
Improved understanding of the physiology of vascular grafts
used for myocardial revascularization has allowed us to
improve their therapeutic management [19-22]. It is well
established that venous grafts degenerate over time (due to
accelerated atherosclerosis in the graft) and that this cor-
relates with the recrudescence of patients’ symptoms [23].
The degeneration process begins in the operating room and
is particularly active in the first year after the procedure
[24]. When it comes to slowing such degeneration down,
systematic re-evaluation of our patients helped correct
prescription errors, notably vis-à-vis statins and angiotensin
converting enzyme inhibitors [19, 21, 22, 25]. We therefore
hope that this strategy can help protect venous grafts
against atherosclerotic damage. Moreover, we observed
that about one patient in three was suffering from residual
ischemia according to a scintigraphic examination. This
ischemia (pointing to incomplete revascularization) itself
constitutes a major risk factor. Our protocol allows us to
step up anti-ischemic treatment and consider secondary
angioplasty. Finally, we observed that atherosclerosis of
peripheral vessels and the vessels of the neck was common:
sustained cardiovascular risk could lead to deterioration in
this respect resulting in secondary complications. We are
currently evaluating cardiovascular risk in patients with
endarteritis obliterans in the lower limbs for whom it was
necessary to conduct coronary artery bypass surgery. 
Conclusion
In conclusion, our approach should help optimize patient
care with the ultimate aim of arresting the progression of
atherosclerotic involvement of the original coronary
network as well as preventing graft degeneration, thereby
cutting down secondary ischemic manifestations at the cost
of a three-day hospital stay. We believe that this cost (com-
pared with outpatient care) should be weighed up against
those of all the professional health care providers (doctors,
physical, therapists, nurses, dietitians, psychologists, etc.)
and tests (ultrasound, scintigraphy, Doppler, etc.) that
might otherwise have to be administered to obtain the
same reduction in risk level. We are currently in the process
of working on how to implement such a strategy at an ear-
lier stage in collaboration with re-education units, espe-
cially for patients at the highest risk. Finally, the real bene-
fits of this type of strategy can only be ascertained after a
far longer follow-up period.
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